<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634371</url>
  </required_header>
  <id_info>
    <org_study_id>Versión 3- BIO 096</org_study_id>
    <nct_id>NCT03634371</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Levothyroxine Sodium Tablets 150 mcg</brief_title>
  <official_title>Bioequivalence Study of Levothyroxine Sodium Tablets 150 mcg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tecnoquimicas</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tecnoquimicas</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the bioequivalence of two levothyroxine&#xD;
      formulations through the estimation of T4 levels in serum samples after baseline correction,&#xD;
      according to Food and Drugs Administration (FDA), World Health Organization (WHO) and&#xD;
      Colombian National Vigilance Institute for Drugs and Food (INVIMA) guidelines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Levothyroxine (T4) is used to treat patients with hypothyroidism and may often result in&#xD;
      lifelong therapy. Its physiologically active metabolite is tri-iodothyronine (T3).&#xD;
      Levothyroxine is also endogenously produced in the body. Since small changes in levothyroxine&#xD;
      administration (e.g. change in brand or formulation) can cause significant changes in serum&#xD;
      thyroid stimulating hormone (TSH) concentrations, precise and accurate TSH control is&#xD;
      critical to avoid potential adverse iatrogenic effects. Tecnoquimicas modified its&#xD;
      Levothyroxine tablets formulation in order to comply with new pharmacopeical specifications.&#xD;
      It will then evaluate the impact on drug product performance based on pharmacokinetic (PK)&#xD;
      measures of total serum T4 and total serum T3 of the new formulation of levothyroxine (Test&#xD;
      formulation) relative to the reference formulation from Merck (Reference formulation)&#xD;
&#xD;
      This will be a single-center, open-label, two-period, two-treatment, two-sequence,&#xD;
      randomized, single-dose, crossover study. 80 healthy adults will be randomized to receive a&#xD;
      single dose (4 x 150 mcg tablets = 600 mcg) of the test formulation of levothyroxine and&#xD;
      reference formulation of levothyroxine separately in each treatment period. There will be two&#xD;
      treatment sequences (AB, BA) and a 42 day washout between the two treatment periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Anticipated">October 6, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(AUC) Area Under the Curve 0-48 for T4</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>-0.5, -0.25, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for T4</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>-0.5, -0.25, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC 0-48 for T3</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>-0.5, -0.25, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for T3</measure>
    <time_frame>From 0 to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>-0.5, -0.25, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>-0.5, -0.25, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test Formulation of Levothyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levothyroxine sodium tablets 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference formulation of Levothyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eutirox 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Levothyroxine 150 mcg</intervention_name>
    <description>Administration of a 600 mcg levothyroxine dose</description>
    <arm_group_label>Test Formulation of Levothyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Eutirox 150 mcg</intervention_name>
    <description>Administration of a 600 mcg levothyroxine dose</description>
    <arm_group_label>Reference formulation of Levothyroxine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and Women from 18 to 50 years old&#xD;
&#xD;
          -  Diagnosed as healthy after a clinical examination&#xD;
&#xD;
          -  BMI from 18 to 30 kg/m2&#xD;
&#xD;
          -  Not smoking for at least 3 months&#xD;
&#xD;
          -  To sign the informed consent&#xD;
&#xD;
          -  Not having participated in a similar study for at least 4 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal, cardiac immunological, dermatological, endocrine, gastrointestinal,&#xD;
             neurological or psychiatric condition&#xD;
&#xD;
          -  Hematologic disorders, specially anemia and polycythemia&#xD;
&#xD;
          -  Permanent or temporal pharmacological therapy, prescribed or not&#xD;
&#xD;
          -  Smoking for the last 3 months&#xD;
&#xD;
          -  Alcohol drinker more than once a week&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Drug hypersensitivity&#xD;
&#xD;
          -  Angioedema or anaphylaxis history&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  HIV o Hepatitis B diagnosed&#xD;
&#xD;
          -  Blood donor in the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universidad de la Sabana</name>
      <address>
        <city>Chía</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>August 14, 2018</last_update_submitted>
  <last_update_submitted_qc>August 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tecnoquimicas</investigator_affiliation>
    <investigator_full_name>Mauricio Vargas</investigator_full_name>
    <investigator_title>Biopharmaceutical Studies Director</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

